![](/img/cover-not-exists.png)
Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): Results from Keynote-052
Castellano, D., Grivas, P., Plimack, E., Balar, A., O’Donnell, P., Bellmunt, J., Powles, T., Hahn, N., De Wit, R., Bajorin, D., Ellison, M.C., Frenkl, T., Keefe, S., Vuky, J.Volume:
17
Language:
english
Journal:
European Urology Supplements
DOI:
10.1016/S1569-9056(18)30938-2
Date:
March, 2018
File:
PDF, 86 KB
english, 2018